FDA sent warning letters to dozens of telehealth companies in 2025 and 2026 over how they marketed compounded GLP-1s. Brands moving to new service lines need a fresh prescribing analysis, a sourcing check and a hard look at their marketing claims. The package delivers all three for one new service line, for your counsel to review.
Who it is for: Cash-pay telehealth brands changing service lines, for example away from compounded GLP-1s.
What's included
- Prescribing matrix for the new service line
- Pharmacy sourcing checklist
- Inventory of your marketing claims, checked against the language FDA cited
- Transition checklist for existing patients
Responses to any FDA or state warning letter are your counsel’s work.
Questions
- Can you rewrite our ads?
- We flag the claims that look like the ones FDA cited and explain why. Your marketing team or agency rewrites them, and your counsel signs off.